Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated June 16, 2023, with details from its quarterly report on Form 10-Q. The supplement relates to the issuance of 2,270,000 shares of common stock, Class A and Class B Common Warrants to purchase up to 2,270,000 shares of common stock each, Pre-Funded Warrants to purchase up to 2,270,000 shares of common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The prospectus supplement, which includes the Quarterly Report, must be read in conjunction with the original prospectus...Show More

Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated June 16, 2023, with details from its quarterly report on Form 10-Q. The supplement relates to the issuance of 2,270,000 shares of common stock, Class A and Class B Common Warrants to purchase up to 2,270,000 shares of common stock each, Pre-Funded Warrants to purchase up to 2,270,000 shares of common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The prospectus supplement, which includes the Quarterly Report, must be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The report also mentions the company's reliance on third-party CROs for clinical trials and the risk of delays if the company fails to meet payment obligations. Panbela Therapeutics has incurred significant losses since its inception and continues to face risks related to the need for additional financing and the success of its development efforts.